Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BI 765179 + Ezabenlimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BI 765179||BI765179|BI-765179||TNFRSF9 Antibody 23||BI 765179 is a bispecific antibody that targets TNFRSF9 (CD137; 4-1BB) expressed on immune cells and fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts, which potentially results in activation of immune cells and a T-lymphocyte mediated immune response against tumor cells (NCI Drug Dictionary).|
|Ezabenlimab||BI754091|BI-754091|BI 754091||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04958239||Phase I||BI 765179 + Ezabenlimab BI 765179||A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)||Recruiting||USA | ESP | BEL||2|